Dexcom is poised to share new data on the benefits of its continuous glucose monitoring technology (CGM), which the company says reinforces the need to broaden CGM access beyond insulin-treated populations.
The full data from several studies by Dexcom will be shared during the Advanced Technologies and Treatments for Diabetes (ATTD) conference, taking place in Barcelona from 11-14 March.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Data from Dexcom’s multi-centre primary care registry will highlight that after one year of Dexcom G7 use, patients with type 2 diabetes not using insulin see significant improvement in blood sugar levels (per A1C testing) and weight management. According to Dexcom, this data supports the importance of access to its CGM systems for “all people with type 2 diabetes”.
Dexcom will also present claims data reporting, indicating that lower diabetic ketoacidosis (DKA)-related hospitalisations and emergency room visits occur for children and adults with type 1 diabetes when the company’s CGM system is used.
According to a GlobalData market model, the CGM market is growing at a CAGR of 9.85% and projected to reach a valuation of $15.69bn in 2035.
Meanwhile, during other sessions at ATTC, Dexcom will provide updates on its existing product roadmap for its G7 and G7 15-Day CGMs, Dexcom ONE+ customer app, and Stelo and Clarity products for diabetes management. Dexcom’s next-generation sensor will also be teased.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDexcom’s CEO, Jake Leach, commented: “The data presented at ATTD reinforces the need for Dexcom CGM to become the standard of care for all people with Type 2 diabetes, including those not using insulin.
“That growing body of evidence, combined with our continued innovation across the Dexcom portfolio, reflects our broader ambition to transform diabetes care and advance metabolic health worldwide.”
During the J.P. Morgan Healthcare conference in January 2026, Leach previously discussed Dexcom’s ambition to drive growth in its international markets by raising awareness and expanding CGM access.
Dexcom held the second-largest CGM market share in the US in 2025 at 44.7%, trailing Abbott in pole position with a 48.5% share, as per a GlobalData market model. However, in territories including Europe, the Asia Pacific (APAC) region and the Middle East & Africa (MEA), Dexcom’s market share is dwarfed by leader Abbott.
Dexcom achieved revenues of $4.66bn in 2025, reflecting a 16% reported rise compared to 2024’s performance at around $4bn.
